Here, we showed that both the GLP‐1 analog exendin‐4 and the DPP‐4 inhibitor saxagliptin improved the diabetes phenotype, mitigated heart damage, hyperglycemia, insulin resistance, myocardial remodeling, and cardiac dysfunction. Here, DPP4 is linked to diabetes mellitus.